NCT03982589

Brief Summary

the investigators studied the impact of severe stress (in this case any event or illness leading to a necessity of critical care) on telomere length.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2018

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

June 10, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 11, 2019

Completed
Last Updated

June 25, 2019

Status Verified

June 1, 2019

Enrollment Period

6 months

First QC Date

June 10, 2019

Last Update Submit

June 23, 2019

Conditions

Acute DiseaseTelomere Shortening

Outcome Measures

Primary Outcomes (1)

  • telomere length difference

    the difference between telomere length in percent between samples taken

    7 days

Secondary Outcomes (2)

  • correlation between mortality and telomere length

    6 month

  • correlation between telomere length change and leukocytes count change

    7 days

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

adults (male and females) admitted to the ICU

You may qualify if:

  • Patients hospitalized up to 72 hours prior to admission to the ICU
  • Predicted ICU stay is at least 5 days

You may not qualify if:

  • Pregnancy and lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rabin medical center

Petah Tikva, Israel

Location

Biospecimen

Retention: SAMPLES WITH DNA

telomere extracted from white blood cells (WBC) anonymously

MeSH Terms

Conditions

Acute Disease

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 10, 2019

First Posted

June 11, 2019

Study Start

October 1, 2017

Primary Completion

March 30, 2018

Study Completion

September 30, 2018

Last Updated

June 25, 2019

Record last verified: 2019-06

Locations

IL(1)